Endo Clinical Biochemical Investigation Anabolic Steroid Abuse Low Hdl

---
name: endo-clinical-biochemical-investigation-anabolic-steroid-abuse-low-hdl
description: Advises clinical or biochemical investigation for anabolic steroid abuse when encountering isolated low HDL‑C (<30 mg/dL) without elevated triglycerides. Typical triggers include a patient with HDL‑C <30 mg/dL and normal TG, suspected anabolic steroid use with isolated low HDL, or investigating drug abuse during a dyslipidemia workup.
---

# Advise clinical or biochemical investigation of anabolic steroid abuse in low HDL without hypertriglyceridemia

## STEP 1 — Gather Information
Collect fasting lipid panel (HDL‑C, TG, LDL‑C), review medication/supplement use, athletic training history, and look for physical signs of androgen excess (acne, gynecomastia, testicular atrophy, rapid weight gain).  
**Decision:** If HDL‑C <30 mg/dL and TG ≤150 mg/dL, proceed to Step 2; otherwise evaluate other causes of low HDL.

## STEP 2 — Rule In / Rule Out
Is HDL‑C <30 mg/dL with normal triglycerides (TG ≤150 mg/dL)?  
- **Yes:** Move to Step 3 to assess suspicion of anabolic steroid abuse.  
- **No:** Rule out isolated low HDL due to steroid abuse; investigate alternative etiologies (e.g., genetic HDL deficiency, hypothyroidism, hepatic disease).

## STEP 3 — Classify or Stratify
Assess for clinical clues of anabolic steroid use: rapid muscle gain, severe acne, gynecomastia, testicular atrophy, mood changes, undisclosed supplement use.  
- **High suspicion:** ≥2 clinical clues present.  
- **Low suspicion:** 0‑1 clinical clue.

## STEP 4 — Decide
- **High suspicion:** Order confirmatory biochemical tests (total testosterone, LH, FSH, SHBG) and consider a urinary steroid metabolite panel; discuss findings with patient and advise cessation if confirmed.  
- **Low suspicion:** Repeat lipid panel in 4–6 weeks, reinforce lifestyle measures, and reassess if HDL remains low.

## Clinical Guardrails / Mimics / Pitfalls
Do not mistake familial HDL deficiency (APOA1/ABCA1 mutations) for steroid abuse; avoid overlooking hypothyroidism, cholestatic liver disease, or nephrotic syndrome as causes of low HDL; refrain from accusing patients without objective biochemical evidence; be aware that some over‑the‑counter supplements may contain undisclosed anabolic steroids.

## Concrete Clinical Example
A 22‑year‑old male bodybuilder presents with HDL‑C 22 mg/dL, TG 80 mg/dL, LDL‑C 95 mg/dL, and reports recent 10 kg muscle gain, facial acne, and use of a “performance” supplement. Physical exam shows mild gynecomastia. With HDL‑C <30 mg/dL and normal TG, high suspicion (≥2 clues) prompts a urinary steroid screen that detects exogenous metabolites; counseling leads to supplement discontinuation and lipid follow‑up.

**Source:** Lipid Management in Patients with Endocrine Disorders: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2020, doi:10.1210/clinem/dgaa674